Considering that PTH1 receptor agonists are indicated for treating patients with primary osteoporosis who have high risk of fracture, and high prices of these drugs, the PTH1 receptor agonists are also recommended for patients with GIOP who have similarly high risk of fragility fractures. This evidence concerns the gene PTH1R and osteoporosis.